AI’s and Spatial Biology’s Potential for Curing Cancer, w/ Nucleai CEO Avi Veidman
AI and spatial biology's potential for mapping cancer cells and developing cures.
Guest
Avi Veidman
Co-founder and CEO, Nucleai
Avi Veidman is co-founder and CEO of Nucleai, which applies artificial intelligence to spatial biology and pathology. Drawing on more than two decades in Israeli intelligence, he helped translate experience in mapping complex environments into tools for analyzing tissue and discovering biomarkers relevant to cancer research.
About this conversation
For over 20 years, Avi Veidman served in the Israeli intelligence forces, and he used AI to to map the world. In the military he used AI for national defense, and he learned its power.
He then realized that just as AI could map a battlefield, it could map cancer cells in biopsies and pathology slides.
Enter Nucleai, his company that’s using AI to improve the science of “spatial biology,” which can ultimately unlock new treatments and cures…with cancer on their radar.
Avi and I get into how this all works, the staggering potential, and the real-world challenges that need to be overcome.
Nucleai
https://nucleai.ai
Merck’s $14 million investment in Nucleai:
https://www.businesswire.com/news/home/20240403580481/en/Merck’s-Corporate-Venture-M-Ventures-Arm-Backs-Nucleai-to-Advance-Its-First-in-class-Spatial-AI-Biomarker-in-Active-Clinical-Enrollment